SCCM Resource Library-Which Vasopressor Do I Pick From My Toolbox?

Video Transcription

Video Summary

The video features discussions on shock and vasopressors by two doctors. Dr. Jamie Gray focuses on blood pressure thresholds and vasopressor use, highlighting the need to balance increasing mean arterial pressure (MAP) with minimizing adverse effects. She presents studies comparing high and low MAP targets and vasopressor strategies but finds inconclusive results, stressing the need for further data. Dr. Ashish Khanna discusses the evolution of vasopressors and landmark trials comparing different medications. He notes that while vasopressors can achieve hemodynamic stability, their direct impact on mortality in the ICU is uncertain. Dr. Khanna mentions the potential benefits of angiotensin II as a vasopressor and suggests that catecholamine-sparing strategies and adjunctive therapies may be the future of sepsis treatment. The transcript, on the other hand, focuses on the cost-effectiveness of vasopressor medications in septic shock treatment. The speaker emphasizes multimodal therapy and discusses the use of steroids and vitamins in combination with vasopressors. They introduce a cost-effectiveness analysis model that evaluates different vasopressors, with vasopressin deemed the most cost-effective. The importance of personalized medicine, maintaining adequate mean arterial pressure, and considering higher MAP goals in specific patient populations is also discussed. Ultimately, both the video and transcript stress the need for individualized care, further research, and cost-effectiveness considerations in using vasopressors.

Asset Subtitle

Pharmacology, Shock Non Sepsis, 2020

Asset Caption

The Society of Critical Care Medicine's Critical Care Congress features internationally renowned faculty and content sessions highlighting the most up-to-date, evidence-based developments in critical care medicine. This is a presentation from the 2020 Critical Care Congress held February 16-19, 2020, in Orlando, Florida, USA.

Learning Objectives

Discuss the use of vasopressors in precise patient clinical scenarios during resuscitation in sepsis and septic shock
Explore new and novel vasopressors in comparison with older vasopressors as an evidence base to evaluate the role of each during evolution of therapy over the past two decades
Define and describe the effects of different degrees of hypotension in critically ill patients in the ICU
Analyze the effects of vasopressor costs with clinical outcomes during the course of patient treatment

Defining and Defending a Mean Arterial Pressure in Vasodilatory Shock

Jaime Robenolt Gray

Evolution of Vasopressors Over the Past Two Decades: Where Is the Evidence?

Ashish K. Khanna

Cost Effectiveness Versus Outcome Effectiveness: Is There a Right Balance?

Simon W. Lam

Meta Tag

Content Type Presentation

Knowledge Area Pharmacology

Knowledge Area Shock Non Sepsis

Knowledge Level Foundational

Membership Level Select

Membership Level Professional

Membership Level Associate

Tag Vasoactive Agents

Tag Economics

Tag Shock

Year 2020

Keywords

shock

vasopressors

mean arterial pressure

adverse effects

vasopressor strategies

landmark trials

sepsis treatment

cost-effectiveness

steroids

personalized medicine

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.